Effects of intra-arterial octreotide on pancreatic texture: a randomized controlled trial

What Was Tested

Researchers studied Octreotide in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

A single-center, prospective, double-blinded, randomized controlled trial with parallel assignment was conducted.

The investigator performing the durometer measurements and pathologist were masked to group assignment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

Because people in this Octreotide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Octreotide, so expectations could not easily colour the readings.

The Octreotide group and the comparison group ran side by side rather than switching.

Pancreatic hardness was measured before, early, and late after intervention.

Analysis was by intention to treat.

This trial is registered at http://www.clinicaltrials.gov (ID NCT01400100).

What Was Measured

The subject headings attached to it are Anastomosis, Surgical, Arteries, Duodenum, Gastrointestinal Agents, Hardness, Hardness Tests and Intraoperative Care.

Author keywords: Octreotide, durometer, gastroduodenal artery, histological score, pancreatic hardness and pancreatoduodenectomy.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Octreotide.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society), a journal based in England.

More context: the Octreotide compound page, all human trials.